Avacincaptad pegol and pegcetacoplan have similar 12-month outcomes in slowing GA, with pegcetacoplan requiring fewer injections.

Uplizna gains new indication; Vanrafia approved for proteinuria in IgAN; Erzofri now available for schizophrenia; setmelanotide shows promise in hypothalamic obesity; GLP-1RAs may reduce dementia risk ...